title: Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.
abstract: Gefitinib and erlotinib are first-generation small molecular inhibitors of EGFR tyrosine kinase activity. To the best of our knowledge, to date, two reports have stated that patients with NSCLC who develop severe hepatotoxicity secondary to gefitinib treatment can be safely switched to erlotinib. However, the reverse situation has not been reported. Here, we present the first case with non-small cell lung cancer harboring EGFR mutation who developed grade 3/4 hepatotoxicity after initiation of erlotinib, which resolved when therapy was changed to gefitinib. As far as we know, this is the first report showing the efficacy of gefitinib for a non-small cell lung cancer patient who developed severe hepatotoxicity while under erlotinib therapy.
authors.affiliation: Department of Respiratory Medicine, Kurashiki Central Hospital, Japan. kk11900@kchnet.or.jp
authors.forename: Kei
authors.initials: K
authors.lastname: Kunimasa
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Yoshioka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iwasaku
authors.forename: Akihiro
authors.initials: A
authors.lastname: Nishiyama
authors.forename: Yohei
authors.initials: Y
authors.lastname: Korogi
authors.forename: Gen
authors.initials: G
authors.lastname: Masuda
authors.forename: Takuya
authors.initials: T
authors.lastname: Takaiwa
authors.forename: Tadashi
authors.initials: T
authors.lastname: Ishida
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib